Cidara Therapeutics Net Profit Margin 2014-2022 | CDTX

Cidara Therapeutics net profit margin from 2014 to 2022. Net profit margin can be defined as net Income as a portion of total sales revenue.
Cidara Therapeutics Net Profit Margin Historical Data
Date TTM Revenue TTM Net Income Net Margin
2022-09-30 $0.06B $-0.03B -55.74%
2022-06-30 $0.03B $-0.06B -237.04%
2022-03-31 $0.05B $-0.04B -77.78%
2021-12-31 $0.05B $-0.04B -85.71%
2021-09-30 $0.05B $-0.05B -106.52%
2021-06-30 $0.04B $-0.05B -119.51%
2021-03-31 $0.01B $-0.08B -690.91%
2020-12-31 $0.01B $-0.08B -625.00%
2020-09-30 $0.01B $-0.07B -670.00%
2020-06-30 $0.03B $-0.05B -170.37%
Sector Industry Market Cap Revenue
Medical Medical - Biomedical and Genetics $0.127B $0.050B
Cidara Therapeutics, Inc. is a biotechnology company. The company is focused on the discovery, development and commercialization of novel anti-infectives. Its product pipeline includes CD101 IV, a long-acting echinocandin antifungal, CD101 topical and C001 which are in different clinical trial. The company developed its product using Cloudbreak(TM) immunotherapy platform. Cidara Therapeutics, Inc. is headquartered in San Diego, California.
Stock Name Country Market Cap PE Ratio
Bristol Myers Squibb (BMY) United States $141.122B 8.73
GSK (GSK) United Kingdom $75.298B 9.44
Bio-Rad Laboratories (BIO.B) United States $13.735B 32.61
QIAGEN (QGEN) Netherlands $10.439B 19.34
Ginkgo Bioworks Holdings (DNA) United States $2.570B 0.00
Arcus Biosciences (RCUS) United States $1.208B 0.00
Biohaven (BHVN) United States $0.950B 0.00
Emergent Biosolutions (EBS) United States $0.405B 0.00
ADC Therapeutics SA (ADCT) Switzerland $0.161B 0.00
Enzo Biochem (ENZ) United States $0.109B 0.00
SQZ Biotechnologies (SQZ) United States $0.016B 0.00
Gelesis Holdings (GLS) United States $0.015B 0.00